Profile data is unavailable for this security.
About the company
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Its clinical-stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses. Its preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach shall potentially treat, or even prevent, metastatic disease. Its product candidates include CLD-101 for Recurrent HGG; CLD-201 for Advanced Solid Tumors, and CLD-400 (RTNova) for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline product candidates, the Company's is also engaged in discovery research of CLD-301 (AAA) for multiple Indications.
- Revenue in USD (TTM)0.00
- Net income in USD-29.98m
- Incorporated2021
- Employees41.00
- LocationCalidi Biotherapeutics Inc4475 Executive Drive, Suite 200SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 794-9600
- Fax+1 (858) 794-9605
- Websitehttps://www.calidibio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weed Inc | 0.00 | -5.19k | 8.70m | 2.00 | -- | 80.95 | 222.15 | -- | -0.00001 | -0.00001 | 0.00 | 0.0009 | 0.00 | -- | -- | 0.00 | -0.4942 | -385.93 | -9.56 | -822.37 | -- | -- | -- | -- | -- | -23.03 | 0.5461 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -7.35m | 8.92m | 8.00 | -- | 3.23 | -- | -- | -0.4739 | -0.4739 | 0.00 | 0.1642 | 0.00 | -- | -- | 0.00 | -96.75 | -- | -119.37 | -- | -- | -- | -- | -- | -- | -5.28 | 0.2542 | -- | -- | -- | -112.71 | -- | -- | -- |
| Notable Labs Ltd | 311.00k | -12.39m | 9.02m | 16.00 | -- | 0.7811 | -- | 29.00 | -2.31 | -2.31 | 0.0622 | 1.28 | 0.0142 | -- | -- | 19,437.50 | -56.70 | -52.02 | -74.10 | -62.09 | 37.30 | 60.19 | -3,984.24 | -3,636.93 | -- | -- | 0.0271 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Oragenics Inc | 20.63k | -20.26m | 9.05m | 5.00 | -- | 8.77 | -- | 438.73 | -7.98 | -7.98 | 0.0079 | 0.5859 | 0.0026 | -- | -- | 4,126.00 | -258.71 | -97.60 | -312.34 | -106.24 | -- | -- | -98,214.93 | -36,169.75 | -- | -- | 0.0461 | -- | -71.37 | -- | -44.56 | -- | 51.64 | -- |
| Cannapharmarx Inc | 0.00 | 3.69m | 9.14m | 21.00 | 1.71 | -- | 2.40 | -- | 0.0081 | 0.0081 | 0.00 | -0.028 | 0.00 | -- | -- | 0.00 | 42.99 | -131.06 | -- | -- | -- | -- | -- | -- | 0.0034 | -1.02 | -- | -- | -- | -- | 143.24 | -- | -- | -- |
| Pacific Software Inc | 0.00 | -77.46k | 9.36m | 0.00 | -- | 0.3008 | -- | -- | -0.1832 | -0.1832 | 0.00 | 0.7646 | 0.00 | -- | -- | -- | -26.19 | -620.48 | -66.38 | -- | -- | -- | -- | -- | -- | -6.29 | 0.00 | -- | -- | -- | -13.29 | -- | -- | -- |
| Portage Biotech Inc | 0.00 | -144.90m | 9.47m | 7.00 | -- | 0.296 | -- | -- | -7.96 | -7.96 | 0.00 | 1.62 | 0.00 | -- | -- | 0.00 | -111.60 | -19.70 | -113.27 | -26.48 | -- | -- | -- | -- | -- | -- | 0.0087 | -- | -- | -- | -520.10 | -- | -- | -- |
| Enzon Pharmaceuticals Inc | 0.00 | 221.00k | 9.65m | 0.00 | 43.62 | 2.93 | -- | -- | 0.003 | 0.003 | 0.00 | 0.624 | 0.00 | -- | -- | -- | 3.21 | -0.8654 | 3.24 | -0.8851 | -- | -- | -- | -159.43 | -- | -- | 0.00 | -- | -100.00 | -- | 106.71 | -55.86 | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -29.98m | 9.68m | 41.00 | -- | -- | -- | -- | -0.6765 | -0.6765 | 0.00 | -0.4079 | 0.00 | -- | -- | 0.00 | -382.78 | -- | -- | -- | -- | -- | -- | -- | -- | -27.45 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| Vaxxinity Inc | 0.00 | -56.94m | 9.93m | 57.00 | -- | 0.7401 | -- | -- | -0.4499 | -0.4499 | 0.00 | 0.1058 | 0.00 | -- | -- | 0.00 | -75.56 | -- | -111.46 | -- | -- | -- | -- | -- | -- | -- | 0.5308 | -- | -- | -- | 24.31 | -- | -- | -- |
| Coeptis Therapeutics Holdings Inc | 0.00 | -16.31m | 10.04m | 5.00 | -- | 2.26 | -- | -- | -0.5804 | -0.5804 | 0.00 | 0.1197 | 0.00 | -- | -- | 0.00 | -212.70 | -36.90 | -378.58 | -37.81 | -- | -- | -- | -- | -- | -- | 0.349 | -- | -- | -- | 43.40 | -- | -- | -- |
| Psyence Biomedical Ltd | 0.00 | 1.52m | 10.04m | -- | -- | -- | 6.63 | -- | -0.0442 | -0.0442 | 0.00 | -0.3979 | 0.00 | -- | -- | -- | 1.13 | -- | 1.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.63 | -- | -- | -- |
| Eterna Therapeutics Inc | 115.00k | -22.92m | 10.28m | 8.00 | -- | -- | -- | 89.39 | -4.25 | -4.25 | 0.0214 | -0.6307 | 0.0036 | -- | 0.2305 | 14,375.00 | -70.71 | -169.05 | -88.77 | -223.00 | -114.78 | -- | -19,912.17 | -682.61 | -- | -15.55 | 1.64 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
| Universe Pharmaceuticals Inc | 32.31m | -6.16m | 10.66m | 225.00 | -- | 0.268 | -- | 0.3299 | -1.70 | -1.70 | 8.91 | 10.91 | 0.5727 | 7.93 | 2.50 | 143,594.40 | -10.92 | 5.31 | -14.34 | 7.07 | 31.93 | 46.26 | -19.08 | 6.25 | 2.43 | -28.05 | 0.1218 | 0.00 | -19.52 | 2.53 | 29.46 | -- | -21.17 | -- |
Data as of Jun 01 2024. Currency figures normalised to Calidi Biotherapeutics Inc's reporting currency: US Dollar USD
6.02%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Red Wave Investments LLCas of 31 Mar 2024 | 644.60k | 1.80% |
| Cable Car Capital LLCas of 31 Mar 2024 | 472.76k | 1.32% |
| Meteora Capital LLCas of 31 Mar 2024 | 249.81k | 0.70% |
| Spectrum Asset Management, Inc. (California)as of 31 Mar 2024 | 166.49k | 0.47% |
| Finepoint Capital LPas of 31 Mar 2024 | 125.00k | 0.35% |
| Polar Asset Management Partners, Inc.as of 31 Mar 2024 | 125.00k | 0.35% |
| Geode Capital Management LLCas of 31 Mar 2024 | 107.11k | 0.30% |
| Governors Lane LPas of 31 Mar 2024 | 94.70k | 0.27% |
| Driehaus Capital Management LLCas of 31 Mar 2024 | 94.70k | 0.27% |
| CPR Investments, Inc.as of 31 Mar 2024 | 70.00k | 0.20% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
